Related Experiment Video
Updated: May 29, 2026
07:29
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
[Induction chemotherapy for head and neck epidermoid carcinomas]
F Peyrade1, E Saâda, K Benezery
1Département d'oncologie médicale, centre Antoine-Lacassagne, Nice cedex 2, France.
Summary
Induction chemotherapy with taxane-cisplatinum-5-fluoro-uracil improves survival for head and neck squamous cell carcinoma. However, toxicity limits its use, necessitating individualized treatment decisions.
Area of Science:
- Oncology
- Head and Neck Cancer Treatment
Background:
- Standard treatment for inoperable head and neck squamous cell carcinoma combines radiotherapy and platinum, with limited 5-year survival rates.
- The efficacy of induction chemotherapy has been re-evaluated with the advent of taxane-cisplatinum-5-fluoro-uracil regimens.
Purpose of the Study:
- To evaluate the efficacy of taxane-cisplatinum-5-fluoro-uracil induction chemotherapy compared to standard platinum-based chemoradiotherapy for head and neck squamous cell carcinoma.
- To address the limitations and toxicity associated with taxane-cisplatinum-5-fluoro-uracil regimens.
Main Methods:
- Comparison of taxane-cisplatinum-5-fluoro-uracil (TCFU) triple association with cisplatinum-5-fluoro-uracil (CFU) in head and neck squamous cell carcinoma.
- Analysis of survival data and toxicity profiles for different chemotherapy regimens.
Main Results:
- The TCFU regimen demonstrated improved survival outcomes compared to the CFU regimen.
- Wider adoption of TCFU is constrained by its toxicity and the absence of direct randomized comparisons with optimal dose concomitant chemoradiotherapy.
Conclusions:
- Induction chemotherapy with TCFU offers a survival benefit for head and neck squamous cell carcinoma.
- Treatment decisions between induction chemotherapy and concomitant chemoradiotherapy should be individualized based on patient factors, tumor characteristics, and treatment center capabilities pending further phase III trial results.
Related Concept Videos
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...